Envista (NVST)
Provides dental technologies, consumables, and services through a multi-brand portfolio.
Something off on this page? Send us feedback.
Combines dental technologies, consumables, and services across brands including DEXIS, Kerr, Nobel Biocare, and Ormco. The portfolio is organized between Specialty Products & Technologies and Equipment & Consumables and operates with the Envista Business System.
Brings together more than 30 dental brands, including DEXIS, Kerr, Nobel Biocare, and Ormco, under an independent company created from Danaher's dental platform. Its Specialty Products & Technologies and Equipment & Consumables businesses sell dental technologies, consumables, and services.
Uses the Envista Business System as its foundational operating methodology, with a culture it says is supported by CIRCLe Values. The company maintains the operating model transferred from Danaher while running its dental portfolio as a separate public company.
Completed its IPO and separation from Danaher in 2019; Danaher retained no voting or economic interest in its common stock after the separation.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 18, 2026 | UBS | Reiterate | Rating: —Target: $25 | Target: $27 |
| Sep 3, 2026 | Deutsche Bank | Target | Target: — | Target: $32 |
| Sep 3, 2026 | JP Morgan | Upgrade | ||
| Aug 6, 2026 | Morgan Stanley | Target | Target: $19 | Target: $23 |
| Aug 6, 2026 | Robert W. Baird | Target | Target: $31 | Target: $34 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jul 3, 2026Cash & short-term investments — · Total debt $1.6K · Total assets — · Shareholders' equity —
- Revenue
- $730.5M
- Operating income
- $80.3M
- Net income
- $53.7M
No dividends on record.
| Institutions | ≈ 117.84% | 189.27M shares | |
|---|---|---|---|
| 388 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.90% | 1.44M shares | |
| 17 holders · as of Aug 27, 2026 | |||
| Adds to | 118.74% | ||
160.62M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 118.74%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 11.48% | 18.44M | as of Jun 30, 2026 |
Eaton Vance ManagementInstitution | 9.73% | 15.62M | filed Feb 12, 2021 |
Ariel Investments, LLCInstitution | 6.11% | 9.82M | as of Jun 30, 2026 |
Dimensional Fund Advisors LPInstitution | 5.96% | 9.57M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 4.66% | 7.49M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 20, 2026 | Mischa Reis | officer: SVP, Strategy & Bus. Dev. | −8,000 | $27.50 |
| Feb 10, 2026 | Mischa Reis | officer: SVP, Strategy & Bus. Dev. | −5,634 | $30.00 |
- Dentsply Sirona
Broad dental rival across digital workflows, implants, aligners and consumables
- Align Technology
Leading clear-aligner and intraoral-scanning rival
- Solventum
Dental and orthodontic materials rival in restorative care and brackets
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Envista | $24.29 | +0.43% | $3.93B | 41.7 | 15.4 | 1.4 | +7.1% |
| Dentsply Sirona | $9.95 | −0.05% | $1.99B | — | 6.8 | 0.5 | −4.1% |
| Align Technology | $149.91 | −2.21% | $10.98B | 26.6 | 12.7 | 2.7 | +4.3% |
| Solventum | $89.28 | +0.60% | $15.37B | 10.8 | 13.1 | 1.8 | +2.2% |
| Median | 18.7 | 12.7 | 1.8 | +2.2% |